GRM5 and fragile X syndrome: Recently in FXS clinical study, novel drugs specifically targeting a single receptor system involved in maintaining E/I balance, namely mGluR5, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA), or GABA(B) receptors, have been unsuccessful in clinical trial development [47].